Paul Lountzis
Lountzis Asset Management
Paul Lountzis Abbott Laboratories stake
total: 139
Lountzis Asset Management ABT trades
- Total transactions:
- 6
- New positions:
- 1
- Added:
- 1
- Reduced:
- 4
- Held since:
- 2020 Q2
- Held for:
- 25 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Paul Lountzis holds 6,930 Abbott Laboratories (ABT) shares with a market value of roughly $628.83K accounting for 0.20% of the overall portfolio. To date, the estimated cost basis is nearly $91.58 for "buy" trades and estimated average "sell" price is $104.2. Lountzis Asset Management first purchased ABT in 2020 Q2, initially acquiring 8,825 shares. Since the initial investment in Abbott Laboratories (ABT), Lountzis Asset Management has made 5 more transactions.
When did Paul Lountzis buy Abbott Laboratories (ABT)?
Paul Lountzis first invested in Abbott Laboratories (ABT) in 2020 Q2 at the reported quarter-end price of $91.44 per share.
What's the cost basis of Lountzis Asset Management's ABT stake?
The estimated cost basis for Abbott Laboratories (ABT) stake is around $91.58 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $91.58
- Weighted AVG sell price:
- $104.20
Paul Lountzis's historical trades in Abbott Laboratories
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.20%
|
6,930
|
$90.74
|
$628,828
|
-6.73% (-500)
|
-0.02%
|
|
2026 Q1
|
0.28%
|
7,430
|
$102.67
|
$762,838
|
+1.43% (+105)
|
+0%
|
|
2025 Q4
|
0.33%
|
7,325
|
$125.29
|
$917,749
|
-3.93% (-300)
|
-0.01%
|
|
2023 Q2
|
0.45%
|
7,625
|
$106.10
|
$809,000
|
-11.59% (-1,000)
|
-0.06%
|
|
2022 Q3
|
0.57%
|
8,625
|
$96.70
|
$834,000
|
-2.27% (-200)
|
-0.01%
|
|
2020 Q2
|
0.76%
|
$91.44
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.